| Title |
Oral misoprostol for induction of labour
|
|---|---|
| Published in |
Cochrane database of systematic reviews, June 2014
|
| DOI | 10.1002/14651858.cd001338.pub3 |
| Pubmed ID | |
| Authors |
Zarko Alfirevic, Nasreen Aflaifel, Andrew Weeks |
| Abstract |
Misoprostol is an orally active prostaglandin. In most countries misoprostol is not licensed for labour induction, but its use is common because it is cheap and heat stable. |
Twitter Demographics
The data shown below were collected from the profiles of 62 tweeters who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Germany | 13 | 21% |
| United Kingdom | 7 | 11% |
| Spain | 3 | 5% |
| Finland | 1 | 2% |
| Austria | 1 | 2% |
| Kenya | 1 | 2% |
| France | 1 | 2% |
| Switzerland | 1 | 2% |
| Ireland | 1 | 2% |
| Other | 3 | 5% |
| Unknown | 30 | 48% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 56 | 90% |
| Practitioners (doctors, other healthcare professionals) | 5 | 8% |
| Scientists | 1 | 2% |
Mendeley readers
The data shown below were compiled from readership statistics for 338 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Canada | 2 | <1% |
| Ethiopia | 1 | <1% |
| South Africa | 1 | <1% |
| Unknown | 334 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 55 | 16% |
| Student > Bachelor | 42 | 12% |
| Researcher | 28 | 8% |
| Student > Ph. D. Student | 24 | 7% |
| Other | 23 | 7% |
| Other | 53 | 16% |
| Unknown | 113 | 33% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 135 | 40% |
| Nursing and Health Professions | 31 | 9% |
| Social Sciences | 12 | 4% |
| Agricultural and Biological Sciences | 9 | 3% |
| Psychology | 9 | 3% |
| Other | 21 | 6% |
| Unknown | 121 | 36% |
Attention Score in Context
This research output has an Altmetric Attention Score of 134. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 June 2023.
All research outputs
#292,395
of 24,457,696 outputs
Outputs from Cochrane database of systematic reviews
#501
of 12,922 outputs
Outputs of similar age
#2,495
of 233,445 outputs
Outputs of similar age from Cochrane database of systematic reviews
#9
of 240 outputs
Altmetric has tracked 24,457,696 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 12,922 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 34.6. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 233,445 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 240 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 96% of its contemporaries.